ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2018

Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.

A Abdel-Gadir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.